CINAMOPS: Critical Illness Polyneuropathy and Myopathy: Outcome, Predictors and Longitudinal Trajectories. A cohort study.

Conditions: G62.80
G72.80

Registration Number: DRKS00021753

Lead Sponsor: Schön Klinik Bad Aibling Harthausen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 250

Inclusion Criteria

At least 5 days with invasive Ventilation at ICU, age = 18 years

Exclusion Criteria

Patients in palliative treatment. Neuromuscular or neurological diseases and/ or syndromes leading to a high-grade of muscular weakness: e.g. Guillain-Barré syndrome, myasthenia gravis, amyotrophic lateral sclerosis, cervical myelopathy, porphyria, Lambert-Eaton syndrome, severe vasculitic neuropathy, botulism. Insufficient communicative ability (knowledge of the German language, cognition), which make the execution of the assessments impossible (additionally no relative or legal guardian available as compensation), full motor strength (MRC 5/5) – no paralysis present.

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
• Description of the clinical and post-clinical course of disease in patients with CIP/CIM in comparison to patients with ICUAW without a proven CIP/CIM.<br>• Evaluation of possible prognosis parameters for the medium- and long-term outcomes self-sufficiency, functioning & impairment and quality of life (12, 18 and 24 months after disease onset) of patients with CIP/CIM. <br>• Investigation of the influence of the pre-clinical health status and frailty on the course of rehabilitation of patients with CIP/CIM.

Secondary Outcome Measures

Name	Time	Method
• Examination of robot-assisted therapies in patients with CIP/CIM<br>• Evaluation of psychometric properties (reliability, validity) of the Mini-BESTest in patients with CIP/CIM<br>• Evaluation of practicability and usability of the new approach for the electrophysiological testing<br>• Evaluation of the clinical course and outcome in the subgroup of patients with CIP/CIM after SARS-CoV-19 infection